Glaxosmithkline this morning
announced the immediate recall
of two batches of Children’s
Panadol 1-5 years Suspension from
pharmacies and hospitals.
The trade-level recall of
Strawberry/200mL (batch number
JR130869) and Orange/100mL
(batch JR130697) is due to routine
testing which identified “out of
specification results” showing a
higher amount of paracetamol than
on the label.
The increase doesn’t pose an
immediate risk to children when
used as directed, and on this basis
GSK in consultation with the TGA
determined that a consumer level
recall of the batches is not needed.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Dec 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.